SCHEDULE 13G/A: Wellington Management Affiliates Disclose 5.4% Passive Stake in Haemonetics Corporation

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a 5.4% beneficial ownership stake in Haemonetics Corporation as of March 31, 2025.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP collectively reported beneficial ownership of 2,688,486 shares of Haemonetics Corporation's Common Stock.
• This aggregate amount represents 5.4% of the class of securities.
• The reporting persons hold shared voting power over 2,141,118 shares and shared dispositive power over 2,688,486 shares.
• The filing is an Amendment No. 5 to a Schedule 13G, indicating an update to an existing passive investment position.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Haemonetics Corporation's future performance or outlook.

Industry Context

This filing is a routine disclosure of an institutional investor's passive ownership stake, common in the financial industry for large asset managers like Wellington Management. It does not provide specific insights into broader industry trends or competitive dynamics within the medical device or healthcare sector where Haemonetics operates.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and investor confidence.

Key Dates

Keywords

Haemonetics Corporation, HAE, Wellington Management Group, Wellington Group Holdings, Wellington Investment Advisors Holdings, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock